Lixte Biotechnology Shares Up After Announcing Preclinical Results of its Collaboration with the Netherlands Cancer Institute
Apr 12, 2022 By MarketDepth
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares jumped more than 280% after the company announced new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100, at the Annual Meeting of American Association for Cancer Research (AACR) in New Orleans, LA, on Monday, April 11, 2022.
In brief, LIXTE’s first-in-class lead clinical compound and protein phosphatase 2A (PP2A) inhibitor, LB-100, induces further activation of oncogenic signaling in a number of KRAS-mutant cancers, rendering them particularly vulnerable to anti-cancer therapy. Professor Bernards’ presentation, entitled “Unconventional Approaches to the Treatment of Cancer”, was delivered as part of the events celebrating Professor Bernards’ selection as the awardee of the 2022 AACR Princess Takamatsu Memorial Lectureship.
“we are delighted to be working with Professor Bernards and his team. Professor Bernards’ insights and contributions enable us to take full advantage of the unique anti-cancer properties of LB-100. His creativity in developing new anti-cancer drug combinations has already had a significant impact on cancer care. His current observations of unexpected synergy of LB-100 with a variety of standard agents and with investigational compounds with only modest activity on their own are promising leads to a new approach to cancer chemotherapy.”
John S. Kovach MD, Founder and CEO of LIXTE Biotechnology Holdings, Inc
Lixte Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off.
